Professional Documents
Culture Documents
Course Paediatrics
Module GI
®
©
Prof. Nasir Shah
MCPS, FCPS, MRCGP [INT], FRCGP [INT]
1
NOCTURNAL ENURESIS ®
©
• Involuntary voiding of urine during sleep
• Affects 8% of children aged 4½y and 1.5% at 9 y
• M>F
• Tends to run in families
• Distressing for child and parents
• Effects on emotional and social well-being
Secondary:
• Child was previously dry and newly develops enuresis
• Usual secondary causes like UTI, stress
2
SECONDARY NOCTURNAL ENURESIS ®
©
• Occasionally caused by emotional distress or recent illness
• Consider if the child has been dry for 6 months prior to onset
3
MALTREATMENT: NOCTURNAL ENURESIS ®
©
4
NON-PHARMACOLOGICAL MANAGMENT ®
©
• Reassure parents and children that enuresis is not the child’s
fault
• Advise:
1. That punitive measures should not be taken
2. Limit the impact of bedwetting, e.g., bed protection
3. Regular toileting 4–7 times per day and before bed
4. Avoid caffeine
5
REWARD SYSTEMS ®
©
Reward systems (positive reinforcement)
• Use for agreed behavior (e.g., going to the toilet before bed)
rather than a dry night
®
©
6
AT SCHOOL ®
©
1. Children should be encouraged to void regularly (2-3/daily)
2. A note for the teacher should be written to ensure that the
child is allowed regular access to the bathroom
3. Children should not be expected to wait for scheduled breaks
to void
4. Holding the urine to the last minute must be discouraged
• Alarm therapy
7
ALARM VERSUS PHARMCOLOGICAL TX ®
©
• Neither therapy is superior to the other in efficacy
8
®
©
®
©
9
DURATION OF ALARM THERAPY ®
©
• Parent should participate every night for at least 3 consecutive
months
• Monthly follow-up care
• Continue therapy 1 month after sustained dryness
10
DESMOPRESSIN ®
©
• Usually, specialist initiated
• Synthetic version of ADH, taken at night
• Side effects: Headache, nausea, nasal congestion, nosebleed,
sore throat, cough, flushing, and mild abdominal cramps
• Risk of water overload—advise only one mug of fluid from 1
hour before desmopressin dose to 8 hour afterwards
• Used when alarm is unsuccessful or unsuitable or in
combination with an alarm
®
©
11
DESMOPRESSIN ®
©
• Taken 1 hour before bedtime
• Recommended starting dose for the tablet is 0.2 mg
• Titrated as to a maximum dose of 0.6 mg
12
NASAL MINIRIN?? ®
©
• Because of the risk for severe
hyponatremia, the intranasal
formulation is no longer indicated
for primary enuresis.
IMIPRAMINE ®
©
• Children treated with imipramine had one fewer wet night
per week.
• The relapse rate is high
• Taken 1-2 hours before bedtime
• Dose: 25 mg for patients aged 6-8 years and 50-75 mg for
older children and adolescents.
13
®
©
14
BLADDER TRAINING EXERCISES ®
©
• Not recommended (have not been shown to be effective)
ENCOPRESIS ®
©
• Encopresis is the involuntary discharge of feces
• Also called fecal incontinence
• In most cases, consequence of chronic constipation and
resulting overflow incontinence
• No good data suggest that encopresis is primarily a behavioral
or psychological disorder
• The behavioral difficulties associated with encopresis are
most likely the result of the condition rather than its cause.
15
ENCOPRESIS ®
©
• Most children are continent of feces by 4 years
• Fecal soiling after this age usually occurs during the day
If:
• Soft stool oozes out, causing constant soiling, consider
overflow incontinence secondary to constipation
• A firm stool is passed occasionally in the toilet but usually in
the pants, developmental delay (either mental or social) is
likely
®
©
16
DIAGNOSIS OF ENCOPRESIS ®
©
• Established with the history and physical examination
• Includes rectal examination
PSYCHOLOGICAL ASPECTS ®
©
• Children with encopresis are significantly more likely to have
attention-deficit disorder/hyperactivity (ADHD) than the
general population
17
TREATMENT OF ENCOPRESIS ®
©
• Treatment remains largely experiential and consists of;
TREATMENT OF ENCOPRESIS ®
©
• Dis-impaction by either oral cathartics or a series of enemas
18
POLYETHYLENE GLYCOL 3350 ®
©
®
©
19
®
©
®
©
20
®
©
REFERENCES ®
©
• https://www.nice.org.uk/guidance
• https://www.patient.co.uk
• https://www.aafp.org
• https://www.mayoclinic.org
• https://www.medscape.com
• https://www.who.int
• Oxford Handbook of General Medicine, 5th edition
21
®
©
22